Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845
is tolerated in patients with haematological diseases and lymphoid malignancies.